Aandeel DAWN DAY ONE BIOPHARMACEUTICALS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Day One Biopharmaceuticals, Inc.

Aandelen

DAWN

US23954D1090

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 26-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
14,92 USD +12,94% Intraday-grafiek van Day One Biopharmaceuticals, Inc. -0,27% +2,19%
24/04 DAY ONE BIOPHARMACEUTICALS, INC. : Needham & Co. geeft koopadvies ZM
24/04 Transcript : Day One Biopharmaceuticals, Inc. - Special Call

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Day One Biopharmaceuticals : Corporate Presentation - April 2024
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma
Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment
Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval
Day One Biopharmaceuticals Insider Sold Shares Worth $322,166, According to a Recent SEC Filing
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
Day One Biopharmaceuticals, Inc. Announces Executive Changes
Day One Announces Two New Appointments to Board of Directors
Day One Biopharmaceuticals, Inc. Announces Board Appointments
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Day One Biopharmaceuticals : Change in Certifying Accountants - Form 8-K
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers DAWN
  4. Nieuws Day One Biopharmaceuticals, Inc.
  5. Andere talen